Target Name: EVA1A
NCBI ID: G84141
Other Name(s): FAM176A | EVA1A_HUMAN | Family with sequence similarity 176, member A | protein FAM176A | family with sequence similarity 176, member A | Transmembrane protein 166 | eva-1 homolog A, regulator of programmed cell death | TMEM166 | transmembrane protein 166 | EVA1A variant 1 | Protein eva-1 homolog A | Eva-1 homolog A, regulator of programmed cell death, transcript variant 1

EVA1A: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

EVA1A (FAM176A) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the everin gene family, which encodes for proteins involved in various cellular processes. One of the functions of EVA1A is to regulate the level of protein synthesis in the cell, which is critical for maintaining cellular homeostasis and growth.

EVA1A has also been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target or biomarker makes it an attractive target for researchers to study and develop new treatments.

Diseases associated with EVA1A

EVA1A has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

1.Cancer

EVA1A has been shown to be involved in the development and progression of several types of cancer, including breast cancer, ovarian cancer, and colorectal cancer. Several studies have shown that EVA1A levels are elevated in the cells of individuals with cancer, and that inhibiting EVA1A activity can lead to a reduction in cancer cell proliferation.

2. Neurodegenerative diseases

EVA1A has also been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and progressive damage to the nervous system. EVA1A has has been shown to be involved in the production of misfolded proteins, which can contribute to the development and progression of these conditions.

3. Autoimmune disorders

EVA1A has also been shown to be involved in the development and progression of several autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. These conditions are characterized by an overreactive immune system that leads to inflammation and damage to body tissues. EVA1A has been shown to be involved in the production of autoantibodies, which can contribute to the development and progression of these conditions.

Potential therapeutic applications

EVA1A's potential as a drug target or biomarker makes it an attractive target for researchers to study and develop new treatments for several diseases.

1.Cancer

EVA1A has been shown to be involved in the development and progression of several types of cancer, including breast cancer, ovarian cancer, and colorectal cancer. Drugs or compounds combined with it can inhibit the activity of EVA1A, thereby inhibiting the growth and spread of cancer cells. Effect.

2. Neurodegenerative diseases

EVA1A has also been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Drugs or compounds combined with it can inhibit the activity of EVA1A, thereby inhibiting nerve cell death and disease. Effect.

3. Autoimmune disorders

EVA1A has also been shown to be involved in the development and progression of several autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Drugs or compounds combined with it can inhibit the activity of EVA1A, thereby inhibiting immune cells from attacking body tissues..

Conclusion

EVA1A is a protein that is expressed in various tissues of the body, and it plays a critical role in maintaining cellular homeostasis and growth. Its potential as a drug target or biomarker makes it an attractive target for researchers to study and develop new treatments for several diseases. The inhibition of EVA1A activity can lead to a reduction in cancer cell proliferation, the production of misfolded proteins, and the development of autoantibodies, which can contribute to the development and progression of these diseases. With further research, EVA1A may prove to be a valuable drug target or biomarker for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: Eva-1 Homolog A, Regulator Of Programmed Cell Death

Functions: Acts as a regulator of programmed cell death, mediating both autophagy and apoptosis

More Common Targets

EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H | FAAH | FAAH2 | FAAHP1 | FAAP100 | FAAP20 | FAAP24 | FABP1 | FABP12 | FABP2